Searching for potential synthetic lethal partners for TP53 mutation from the SL-BioDP identified multiple genes from the proteasome pathways as candidate SLs, e.g. PSMA6 and PSMC6 in the breast cancer (BRCA), PSMD3, PSMC4 in bladder cancer (BLCA), PSMA3 in cervical cancer (CESC), PSMG1 in liver cancer (LIHC), PSMD10 in lung adenocarcinoma (LUAD), PSMB1 in ovarian cancer (OV), PSMB4 in pancreatic cancer (PAAD), PSMD7 in kidney renal cancer (KIRC), PSMD1 and PSMC3 in melanoma (SKCM), PSMC1, PSMA5 and PSMA1 in head and neck cancer (HNSC). Here, PSMA6 is linked to bladder transitional cell carcinoma.